STTK (Shattuck Labs, Inc.) — AI Stock Analysis & Recommendation

Research of August 29, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate STTK a BUY. The latest price is $5.49.

The research plan

• Entry: $7.04
• Target: $8.80
• Stop: $5.28
• Time horizon: weeks

The bullish fundamental and sentiment outlook, combined with a technical oversold signal, suggests a potential recovery over a few weeks.

Why

STTK presents a compelling buy opportunity due to strong fundamental and sentiment backing, coupled with a technical oversold signal. Despite the high risk score, the potential for significant upside from its pipeline catalysts, supported by a healthy cash position, warrants a position. The R/R is borderline, but the confluence of bullish factors justifies entry with a tight stop.

What could push STTK higher

• Positive clinical trial data for SL-325, a key pipeline asset.
• Analyst upgrades and increased institutional activity driving positive sentiment.
• Strong cash position providing runway and mitigating near-term dilution risk.

Key risks for STTK

• Pipeline binary event risk, where trial outcomes are critical and uncertain.
• High cash burn rate for a pre-revenue biotech, leading to potential dilution.
• Extreme historical volatility and potential for sharp price reversals.

What each AI research team found

Fundamental team: Bullish · valuation: speculative

Shattuck Labs (STTK) presents a speculative but fundamentally bullish case driven by its promising clinical pipeline and strong cash position. The company's valuation is currently speculative, relying on the successful development of its drug candidates, but the overwhelmingly positive analyst sentiment and significant upside potential to their mean target price support this view. The substantial cash runway into...

• STTK is a clinical-stage biotech with a strong cash position ($63.3M) providing runway into 2029, mitigating near-term dilution risk.
• The company's valuation is driven by its promising pipeline, particularly SL-325, with significant catalysts expected in the near to medium term.
• Analyst consensus is overwhelmingly positive ('Strong Buy') with a mean target price of $14.67, implying substantial upside from the current price.

Technical team: Neutral

The analysis indicates a neutral stance due to conflicting signals between bearish momentum and the potential for a bounce off support. The stock is consolidating within a defined range, with no clear directional bias from volume or trend analysis. A breakout above resistance or breakdown below support is needed for a clearer trading signal.

• The stock is consolidating between support at $6.93 and resistance at $7.66, with a neutral outlook until a clear breakout occurs.
• The stock is trading in a sideways range with mixed volume signals, suggesting a neutral outlook until a clear breakout or breakdown occurs.
• Momentum indicators are showing bearish signs, but the price is consolidating near a support level, suggesting a neutral short-term outlook with potential downside risk.

Sentiment team: Bullish

Shattuck Labs (STTK) exhibits a strong bullish sentiment driven by significant analyst upgrades, promising clinical trial progress for SL-325, and increasing institutional interest. While concerns about cash burn and biotech risks exist, the positive momentum and extended cash runway suggest a favorable outlook for the near to medium term.

• Predominantly positive sentiment driven by strong analyst endorsements and promising clinical pipeline advancements for SL-325, despite concerns regarding recent net losses and stock volatility. (Score: 0.15)
• Cautiously optimistic retail sentiment fueled by analyst upgrades, positive clinical trial news, and technical momentum, with lingering concerns about biotech risks and cash runway. (Score: 0.15)
• Strong positive sentiment from multiple analyst upgrades, significant price target upside, and positive institutional activity, tempered by cash burn and binary development risks. (Consensus: Positive)

Risk team: High

STTK presents a HIGH overall risk profile due to its pre-revenue biotech status, characterized by binary pipeline event risk, significant cash burn, and extreme historical volatility. The potential for substantial dilution and the inherent unpredictability of clinical trial outcomes necessitate a very cautious approach.

• Pipeline Binary Event Risk: The company's value is entirely dependent on binary outcomes from its drug pipeline (clinical trials, regulatory approvals), leading to extreme price volatility.
• Cash Runway and Dilution Risk: Significant cash burn rate for a pre-revenue biotech raises concerns about its runway and the potential for dilutive financing before key catalysts.
• High Realized Volatility and Deep Drawdown: STTK exhibits extremely high historical volatility and has experienced a severe drawdown, indicating substantial downside potential.

STTK at a glance

Market value	$567.6M
Revenue growth (year over year)	-66.6%
Profit margin	-5256.8%
Debt / equity	0.00

Every AI call on STTK since May 5, 2026, and what happened next (9 calls) →

Research of August 29, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.